Merck markets a biosimilar infliximab, Renflexis; a biosimilar trastuzumab, Ontruzant; and a biosimilar etanercept, Brenzys, in partnership with Samsung Bioepis.
Merck said Wednesday it is spinning off its biosimilars business into a new company, along with women’s health products and other brands, in order to focus on its oncology drug pembrolizumab (Keytruda).
Merck markets a biosimilar infliximab, Renflexis; a biosimilar trastuzumab, Ontruzant; and a biosimilar etanercept, Brenzys, in partnership with Samsung Bioepis.
Another biosimilar from the partnership, SB8, a proposed bevacizumab biosimilar referencing Avastin, is under review by the FDA; a decision is expected later this year.
In a company release, Merck said the new firm “is well-positioned to be a partner in the commercialization of biosimilars worldwide.” It will be headquartered in New Jersey (as is Merck), with about 10,000 to 11,000 employees, and will have approximately 75% of sales generated from markets outside of the United States. The spun off products are expected to generate 2020 revenue of approximately $6.5 billion within Merck; as an independent company from a 2021 base-year of approximately $6.0 billion to $6.5 billion in revenue, the new firm is expected to achieve low-single-digit revenue growth.
The new firm's chief executive officer (CEO) will be Kevin Ali, who has spent about 30 years within Merck.
“Over the past several years, we have purposefully shifted the focus of our efforts and resources to our best opportunities for growth,” said Kenneth C. Frazier, Merck's chairman and CEO.
Sales of the 3 biosimilars were about $250 million last year; sales of pembrolizumab were $11 billion, according to The Wall Street Journal.
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
Will the FTC Be More PBM-Friendly Under a Second Trump Administration?
February 23rd 2025On this episode of Not So Different, we explore the Federal Trade Commission’s (FTC) second interim report on pharmacy benefit managers (PBMs) with Joe Wisniewski from Turquoise Health, discussing key issues like preferential reimbursement, drug pricing transparency, biosimilars, shifting regulations, and how a second Trump administration could reshape PBM practices.
The Biosimilar Void: 90% of Biologics Coming Off Patent Will Lack Biosimilars
February 5th 2025Of the 118 biologics losing exclusivity over the next decade, only 10% have biosimilars in development, meaning a vast majority of biologics have no pipeline, which limits savings potential for the health care system.
The Banking of Biosimilars: Insights From a Leading Health Economist
February 4th 2025Biosimilars have the potential to reduce health care costs and expand patient access, but economic and policy barriers affect adoption, explored James D. Chambers, PhD, MPharm, MSc, associate professor at the Tufts Medical Center Institute for Clinical Research and Health Policy Studies, in an interview.